Korean J Dermatol.
2016 Sep;54(8):614-621.
A Clinical Study using Quadrivalent Human Papilloma Virus (HPV) Vaccine for Treatment of Recalcitrant Wart
- Affiliations
-
- 1Department of Dermatology, Maryknoll Medical Center, Busan, Korea. heartthrob80@hanmail.net
- 2Department of Dermatology, Kosin University College of Medicine, Busan, Korea.
Abstract
- BACKGROUND
Although several traditional treatments have been applied for recalcitrant viral warts, these treatments have rarely resulted in complete recovery. To treat the recalcitrant viral wart, alternative therapies are required.
OBJECTIVE
This study aimed to evaluate the efficacy and safety of quadrivalent HPV vaccine for recalcitrant wart treatment.
METHODS
From 2012 to 2014, 17 patients who provided informed consent were enrolled. All patients received 3 doses of quadrivalent HPV vaccine at 0, 2, and 6 months, respectively. During clinic visits, doctors checked the grade of improvement, patient satisfaction, and treatment side effects. After completion of the 3 doses, the patients were followed up for 5 months with outpatient visits and telephone inquiries.
RESULTS
After the third dose, 58.8% of patients showed complete remission and 41.2% showed no response after 5 months. There were no statistically significant differences in sex, age, disease duration, number, anatomic site, and previous treatment between the complete remission group and the no-response group. An adverse effect (syncope) was observed in one patient.
CONCLUSION
Compared with traditional aggressive therapies, quadrivalent HPV vaccine is a simple method and does not usually interfere with the patient's work or social life. Quadrivalent HPV vaccine is an effective and safe alternative treatment for recalcitrant warts.
